OSCAR HEALTH INC

Oscar Health CEO sells 2.8 M shares under Rule 10(b)(5)(1) for tax compliance—no signal of weakness, still strong momentum and a low valuation.

Oscar Health insider buying sparks investor curiosity: insider confidence vs. negative earnings and high social‑media volatility.

Insider buying of Oscar Health’s deferred stock units signals bullish confidence, promising a potential rise toward the 52‑week high if earnings and sentiment improve.

Mark Bertolini’s April insider trades show confidence in Oscar Health’s platform and future EPS targets, signaling potential upside for investors amid a rising healthcare‑tech trend.

Oscar Health insiders buying shares amid cautious cash strategy: CEO and execs’ RSU purchases and sales reveal confidence in long‑term tech‑driven growth and future upside.

Oscar Health insider buys signal confidence in its tech‑driven growth, but investors should watch earnings, enrollment and new partnerships for long‑term value.

Oscar Health’s CTO buys shares amid volatility—insight into exec confidence, market momentum, and growth challenges. Learn how this impacts investors and strategy.